Cerimon Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cerimon Pharmaceuticals Inc.
Market Insight - Rich pickings from reformulations?
In recent years, drug reformulation has emerged as a popular defence strategy among pharmaceutical companies seeking to prolong the life cycles of their best-selling products. It has also attracted growing interest from specialist companies developing novel formulations of off-patent drugs and which either launch them as replacements for the originator products, or reposition them for new indications.
Cerimon receives positive Phase II data on diclofenac patch
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
The industry's genericization problem will seriously constrain Big Pharma's ability to pay for late-stage development on all its products. One potential solution is being developed by Pfizer, whose top R&D execs see out-partnering as a way to free up resources for key programs and to expand R&D capacity. In this interview with R&D boss Martin Mackay, Mackay reports that Pfizer is building up a war-chest of out-licensing and partnering candidates, pursuing a wide variety of transactions--including project financing, straight out-licensing and spinoffs. But the extent of Pfizer's long-term commitment to out-partnering still isn't clear.
Corporate VC Adds a Business Development Flavor
Nearly all the meters on pharma's pipeline are reading critical. With licensing and M&A increasingly a series of high-priced auctions, Big Pharma is casting about, often desperately, for new business-development strategies. And one place they're beginning to look is corporate venture capital, traditionally a way to provide drug companies with a window on new technologies. But that means finding a way to break through the seemingly impenetrable wall between corporate venture investing and other corporate and research activities. Thus, companies have embarked on a number of different strategies, ranging from the traditional to the radically new and aggressive. Getting the equity investor and the asset-hungry pharma partner to co-exist peacefully has aroused plenty of both skepticism and confusion Nevertheless, there's still a promising way for drug companies to get value from start-ups beyond mere equity appreciation--investing de-prioritized drug candidates, not merely capital.
- Specialty Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.